niclosamide has been researched along with 2019 Novel Coronavirus Disease in 16 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (NCL) is an anthelminthic drug, which is widely used to treat various diseases due to its pleiotropic anti-inflammatory and antiviral activities." | 2.72 | Niclosamide for Covid-19: bridging the gap. ( Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Alzahrani, KJ; Batiha, GE, 2021) |
| "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics." | 2.66 | Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ( Li, H; Shi, PY; Xu, J; Zhou, J, 2020) |
| "Niclosamide has been proposed as a possible candidate for a Covid-19 drug." | 1.91 | Production of a major metabolite of niclosamide using bacterial cytochrome P450 enzymes. ( Cha, GS; Choi, SK; Fabelle, NR; Nguyen, NA; Oktavia, FARH; Yun, CH, 2023) |
| "Niclosamide, an oral anthelmintic drug, could inhibit SARS-CoV-2 virus replication through autophagy induction, but high cytotoxicity and poor oral bioavailability limited its application." | 1.91 | Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2. ( Huang, S; Jiang, H; Jiang, X; Li, R; Peng, K; Shen, J; Zhang, B; Zhang, Z, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 16 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, S | 1 |
| Ko, M | 1 |
| Lee, J | 1 |
| Choi, I | 1 |
| Byun, SY | 1 |
| Park, S | 1 |
| Shum, D | 1 |
| Kim, S | 1 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Ahamad, S | 1 |
| Branch, S | 1 |
| Harrelson, S | 1 |
| Hussain, MK | 1 |
| Saquib, M | 1 |
| Khan, S | 1 |
| Rejinold, NS | 1 |
| Piao, H | 1 |
| Jin, GW | 1 |
| Choi, G | 1 |
| Choy, JH | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Alzahrani, KJ | 1 |
| Alexiou, A | 1 |
| Batiha, GE | 1 |
| Ousingsawat, J | 1 |
| Centeio, R | 1 |
| Cabrita, I | 1 |
| Talbi, K | 1 |
| Zimmer, O | 1 |
| Graf, M | 1 |
| Göpferich, A | 1 |
| Schreiber, R | 1 |
| Kunzelmann, K | 1 |
| Hernandez-Clavijo, A | 1 |
| Gonzalez-Velandia, KY | 1 |
| Rangaswamy, U | 1 |
| Guarneri, G | 1 |
| Boscolo-Rizzo, P | 1 |
| Tofanelli, M | 1 |
| Gardenal, N | 1 |
| Sanges, R | 1 |
| Dibattista, M | 1 |
| Tirelli, G | 1 |
| Menini, A | 1 |
| Qayed, WS | 1 |
| Ferreira, RS | 1 |
| Silva, JRA | 1 |
| Fabelle, NR | 1 |
| Oktavia, FARH | 1 |
| Cha, GS | 1 |
| Nguyen, NA | 1 |
| Choi, SK | 1 |
| Yun, CH | 1 |
| Li, R | 1 |
| Zhang, Z | 1 |
| Huang, S | 1 |
| Peng, K | 1 |
| Jiang, H | 1 |
| Shen, J | 1 |
| Zhang, B | 1 |
| Jiang, X | 1 |
| Feng, S | 1 |
| Puchades, C | 1 |
| Ko, J | 1 |
| Wu, H | 1 |
| Chen, Y | 1 |
| Figueroa, EE | 1 |
| Gu, S | 1 |
| Han, TW | 1 |
| Ho, B | 1 |
| Cheng, T | 1 |
| Li, J | 1 |
| Shoichet, B | 1 |
| Jan, YN | 1 |
| Cheng, Y | 1 |
| Jan, LY | 1 |
| Xu, J | 1 |
| Shi, PY | 1 |
| Li, H | 1 |
| Zhou, J | 1 |
| Gupta, SP | 1 |
| Jara, MO | 1 |
| Warnken, ZN | 1 |
| Sahakijpijarn, S | 1 |
| Moon, C | 1 |
| Maier, EY | 1 |
| Christensen, DJ | 1 |
| Koleng, JJ | 1 |
| Peters, JI | 1 |
| Hackman Maier, SD | 1 |
| Williams Iii, RO | 1 |
| Gassen, NC | 1 |
| Papies, J | 1 |
| Bajaj, T | 1 |
| Emanuel, J | 1 |
| Dethloff, F | 1 |
| Chua, RL | 1 |
| Trimpert, J | 1 |
| Heinemann, N | 1 |
| Niemeyer, C | 1 |
| Weege, F | 1 |
| Hönzke, K | 1 |
| Aschman, T | 1 |
| Heinz, DE | 1 |
| Weckmann, K | 1 |
| Ebert, T | 1 |
| Zellner, A | 1 |
| Lennarz, M | 1 |
| Wyler, E | 1 |
| Schroeder, S | 1 |
| Richter, A | 1 |
| Niemeyer, D | 1 |
| Hoffmann, K | 1 |
| Meyer, TF | 1 |
| Heppner, FL | 1 |
| Corman, VM | 1 |
| Landthaler, M | 1 |
| Hocke, AC | 1 |
| Morkel, M | 1 |
| Osterrieder, N | 1 |
| Conrad, C | 1 |
| Eils, R | 1 |
| Radbruch, H | 1 |
| Giavalisco, P | 1 |
| Drosten, C | 1 |
| Müller, MA | 1 |
| Prabhakara, C | 1 |
| Godbole, R | 1 |
| Sil, P | 1 |
| Jahnavi, S | 1 |
| Gulzar, SE | 1 |
| van Zanten, TS | 1 |
| Sheth, D | 1 |
| Subhash, N | 1 |
| Chandra, A | 1 |
| Shivaraj, A | 1 |
| Panikulam, P | 1 |
| U, I | 1 |
| Nuthakki, VK | 1 |
| Puthiyapurayil, TP | 1 |
| Ahmed, R | 1 |
| Najar, AH | 1 |
| Lingamallu, SM | 1 |
| Das, S | 1 |
| Mahajan, B | 1 |
| Vemula, P | 1 |
| Bharate, SB | 1 |
| Singh, PP | 1 |
| Vishwakarma, R | 1 |
| Guha, A | 1 |
| Sundaramurthy, V | 1 |
| Mayor, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niclosamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
Primed for global coronavirus pandemic: Emerging research and clinical outcome.
Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Dr | 2021 |
Niclosamide for Covid-19: bridging the gap.
Topics: Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Niclosamide; | 2021 |
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug R | 2020 |
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
11 other studies available for niclosamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop | 2020 |
Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy.
Topics: Aged; Animals; COVID-19; Humans; Nanoparticles; Niclosamide; Rats; SARS-CoV-2; Serum Albumin, Bovine | 2021 |
Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.
Topics: Animals; Asthma; Cells, Cultured; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Ca | 2022 |
Supporting Cells of the Human Olfactory Epithelium Co-Express the Lipid Scramblase TMEM16F and ACE2 and May Cause Smell Loss by SARS-CoV-2 Spike-Induced Syncytia.
Topics: Angiotensin-Converting Enzyme 2; Anosmia; COVID-19; Giant Cells; Humans; Lipids; Niclosamide; Olfact | 2022 |
In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations.
Topics: Antiviral Agents; COVID-19; Cysteine Endopeptidases; Digitoxin; Digoxin; Drug Repositioning; Humans; | 2022 |
Production of a major metabolite of niclosamide using bacterial cytochrome P450 enzymes.
Topics: Bacterial Proteins; COVID-19; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Microsomes, Liv | 2023 |
Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; Imidazoles; Mice; Niclosamide; SARS-CoV-2 | 2023 |
Identification of a drug binding pocket in TMEM16F calcium-activated ion channel and lipid scramblase.
Topics: Anoctamins; Calcium; Calcium Channels; COVID-19; Humans; Lipids; Niclosamide; Phospholipid Transfer | 2023 |
Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters.
Topics: Administration, Inhalation; Aerosols; Animals; COVID-19; Cricetinae; Dry Powder Inhalers; Freezing; | 2021 |
SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals.
Topics: Animals; Antinematodal Agents; Autophagosomes; Autophagy; Autophagy-Related Proteins; Cells, Culture | 2021 |
Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Cell Line; Chlorocebu | 2021 |